Form 8-K - Current report:
SEC Accession No. 0001193125-25-021878
Filing Date
2025-02-06
Accepted
2025-02-06 17:19:13
Documents
17
Period of Report
2025-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d914904d8k.htm   iXBRL 8-K 66000
2 EX-2.1 d914904dex21.htm EX-2.1 641502
3 EX-99.1 d914904dex991.htm EX-99.1 36084
4 EX-99.2 d914904dex992.htm EX-99.2 46834
5 EX-99.3 d914904dex993.htm EX-99.3 49135
  Complete submission text file 0001193125-25-021878.txt   1145261

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA slrn-20250206.xsd EX-101.SCH 2840
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE slrn-20250206_lab.xml EX-101.LAB 17977
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slrn-20250206_pre.xml EX-101.PRE 11251
19 EXTRACTED XBRL INSTANCE DOCUMENT d914904d8k_htm.xml XML 3612
Mailing Address 4149 LIBERTY CANYON RD. AGOURA HILLS CA 91301
Business Address 4149 LIBERTY CANYON RD. AGOURA HILLS CA 91301 805-456-4393
ACELYRIN, Inc. (Filer) CIK: 0001962918 (see all company filings)

EIN.: 852406735 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41696 | Film No.: 25598439
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)